{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:26:51Z","timestamp":1787574411858,"version":"build-2736575974"},"reference-count":136,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Urothelial carcinoma (UCC) remains a clinical challenge due to its high recurrence rate and aggressive advanced-stage behavior. Driven by a high tumor mutational burden and the consistent overexpression of surface antigens, including Nectin-4, Trop-2, and HER2, UCC has become a prime target for antibody-mediated therapies. Although both immune checkpoint inhibitors (ICIs) and antibody\u2013drug conjugates (ADCs) show significant clinical efficacy, their rational combination further enhances antitumor activity via immunogenic cell death. However, therapeutic resistance and immune evasion still limit response durability in many patients. This review provides a comprehensive overview of the molecular principles, mechanisms of action, and clinical efficacy of antibody-based UCC therapies. Additionally, we analyze biomarkers for patient selection, the mechanisms underlying resistance development, and the rationale for ADC-ICI combinations. By evaluating current challenges and unmet needs, this review aims to clarify the evolving therapeutic landscape and suggest future directions for optimizing UCC treatment.<\/jats:p>","DOI":"10.3390\/cancers18172743","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:47:19Z","timestamp":1787572039000},"page":"2743","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody-Mediated Therapies in Urothelial Carcinoma: A Critical Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"given":"Se-Il","family":"Go","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Science, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon 51472, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9198-8198","authenticated-orcid":false,"given":"Viozzy Florendinha da Costa","family":"Xavier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, 15 Jinju-daero 816 Beon-gil, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Hee","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Science, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon 51472, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-1424","authenticated-orcid":false,"given":"Won Sup","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medical Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, 15 Jinju-daero 816 Beon-gil, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Alouini, S. (2024). Risk Factors Associated with Urothelial Bladder Cancer. Int. J. Environ. Res. Public Health, 21.","DOI":"10.3390\/ijerph21070954"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"04109","DOI":"10.7189\/jogh.13.04109","article-title":"The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040","volume":"13","author":"Zhang","year":"2023","journal-title":"J. Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00345-011-0710-3","article-title":"Predictive factors of recurrence and survival of upper tract urothelial carcinomas","volume":"29","author":"Verhoest","year":"2011","journal-title":"World J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Guerrero-Ramos, F., Gonzalez-Padilla, D.A., Perez-Cadavid, S., Garcia-Rojo, E., Tejido-Sanchez, A., Hernandez-Arroyo, M., Gomez-Canizo, C., and Rodriguez-Antolin, A. (2024). Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs. Cancers, 16.","DOI":"10.3390\/cancers16193330"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"BSR20194337","DOI":"10.1042\/BSR20194337","article-title":"Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer","volume":"40","author":"Lv","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/curroncol29030117","article-title":"Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies","volume":"29","author":"Voutsadakis","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mancini, M., Righetto, M., and Noessner, E. (2021). Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. Cancers, 13.","DOI":"10.3390\/cancers13236016"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15287","DOI":"10.1038\/s41598-023-42495-2","article-title":"The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer","volume":"13","author":"Boll","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.18053\/jctres.07.202104.009","article-title":"Immune escape mechanisms and immunotherapy of urothelial bladder cancer","volume":"7","author":"Yang","year":"2021","journal-title":"J. Clin. Transl. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shin, J., Park, J.W., Kim, S.Y., Lee, J.H., Choi, W.S., and Kim, H.S. (2024). Strategies for Overcoming Immune Evasion in Bladder Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063105"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fan, Y., Li, Q., Shen, Q., Liu, Z., Zhang, Z., Hu, S., Yu, W., He, Z., He, Q., and Zhang, Q. (2022). Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.858865"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-022-04459-7","article-title":"An update on antibody\u2013drug conjugates in urothelial carcinoma: State of the art strategies and what comes next","volume":"90","author":"Chapman","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kwon, W.A., Lee, S.Y., Jeong, T.Y., Kim, H.H., and Lee, M.K. (2024). Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development. Cancers, 16.","DOI":"10.3390\/cancers16132420"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ungaro, A., Tucci, M., Audisio, A., Di Prima, L., Pisano, C., Turco, F., Delcuratolo, M.D., Di Maio, M., Scagliotti, G.V., and Buttigliero, C. (2022). Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Cells, 11.","DOI":"10.3390\/cells11050803"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Brower, B., McCoy, A., Ahmad, H., Eitman, C., Bowman, I.A., Rembisz, J., and Milowsky, M.I. (2024). Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1326715"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: Preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.juro.2015.05.087","article-title":"Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer","volume":"194","author":"Hayashi","year":"2015","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.37349\/etat.2024.00240","article-title":"Landscape of targeted therapies for advanced urothelial carcinoma","volume":"5","author":"Shang","year":"2024","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Liu, D., Xu, S., Chang, T., Ma, S., Wang, K., Sun, G., Chen, S., Xu, Y., and Zhang, H. (2022). Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.916800"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: A novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and Safety of Disitamab Vedotin in Patients with Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1080\/14796694.2025.2561539","article-title":"HERTHENA-PanTumor01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO-25-00109","article-title":"Efficacy and Safety of BL-B01D1 in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial","volume":"43","author":"Bian","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.2025.43.16_suppl.3042","article-title":"First-in-human (FIH) phase 1 study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC), in patients with platinum-refractory\/resistant ovarian cancer and other advanced solid tumors","volume":"43","author":"Patel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/1535-7163.MCT-15-0570","article-title":"Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker","volume":"15","author":"Morrison","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1158\/1078-0432.CCR-22-3627","article-title":"Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma","volume":"30","author":"Petrylak","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_36","first-page":"6519","article-title":"High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder","volume":"15","author":"Xu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(25)00733-8","article-title":"Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): Dose-escalation results from a phase 1\/2 trial","volume":"27","author":"Johnson","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_38","first-page":"7","article-title":"Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway","volume":"6","author":"Lee","year":"2015","journal-title":"Onco. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41598-020-58351-6","article-title":"Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-018-0314-1","article-title":"Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond","volume":"6","author":"Zhu","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/mco2.671","article-title":"Antibody-drug conjugates in cancer therapy: Mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","article-title":"Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: A first-in-human, open-label, multicenter, phase I\/II study","volume":"36","author":"Zhang","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2025.43.16_suppl.4519","article-title":"9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-na\u00efve patients with locally advanced or metastatic urothelial carcinoma (la\/mUC): Results from a phase 1b\/2 study","volume":"43","author":"Jiang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2026.44.16_suppl.4518","article-title":"Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la\/mUC): Follow-up results from a phase 1b\/2 study","volume":"44","author":"Sheng","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-23-0287","article-title":"Raludotatug deruxtecan, a CDH6-targeting antibody\u2013drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models","volume":"23","author":"Suzuki","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.23.01720","article-title":"TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy","volume":"42","author":"Petrylak","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_55","unstructured":"U.S. Food and Drug Administration (2026, August 20). FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer. Updated 22 November 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2026.01.015","article-title":"Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer","volume":"90","author":"Tateo","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa2601486","article-title":"Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer","volume":"395","author":"Galsky","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_64","first-page":"121","article-title":"Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer","volume":"3","author":"Lei","year":"2023","journal-title":"J. Nat. Cancer Cent."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Ralser","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ccell.2026.04.010","article-title":"Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer","volume":"44","author":"Wang","year":"2026","journal-title":"Cancer Cell"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Hammood, M., Craig, A.W., and Leyton, J.V. (2021). Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)\u2014A necessity for future ADC research and development. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070674"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Abelman, R.O., Wu, B., Spring, L.M., Ellisen, L.W., and Bardia, A. (2023). Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers, 15.","DOI":"10.3390\/cancers15041278"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Hatogai, K., and Sweis, R.F. (2021). The tumor microenvironment of bladder cancer. Tumor Microenvironments in Organs: From the Brain to the Skin\u2014Part B, Springer.","DOI":"10.1007\/978-3-030-59038-3_17"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"101792","DOI":"10.1016\/j.xcrm.2024.101792","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_73","first-page":"e11498","article-title":"HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies","volume":"12","author":"Capone","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2217\/imt-2020-0336","article-title":"PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: Between a dream and a nightmare","volume":"13","author":"Zouein","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zhao, X., Bao, Y., Meng, B., Xu, Z., Li, S., Wang, X., Hou, R., Ma, W., Liu, D., and Zheng, J. (2022). From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1\/PD-L1 blockades. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.920021"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1097\/JS9.0000000000001372","article-title":"Prognostic significance of circulating tumor DNA in urothelial carcinoma: A systematic review and meta-analysis","volume":"110","author":"Liu","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.euo.2024.12.006","article-title":"Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data","volume":"8","author":"Jindal","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Huang, J., Ojo, A., and Liaw, B. (2026). Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma. Curr. Oncol., 33.","DOI":"10.3390\/curroncol33020103"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Goldenberg, D.M., and Sharkey, R.M. (2019). Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MABS, Taylor & Francis.","DOI":"10.1080\/19420862.2019.1632115"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"23523735251317865","DOI":"10.1177\/23523735251317865","article-title":"Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer","volume":"11","author":"Shanmugam","year":"2025","journal-title":"Bladder Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Wang, P., and Xia, L. (2023). RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: A real-world study. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11593-9"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Wummer, B., Schwartz, M., Ciuro, J., Ahmed, S., Joshi, S.S., Narayan, V.M., Carthon, B.C., Bilen, M.A., and Brown, J.T. (2025). Overcoming resistance in advanced urothelial carcinoma: Mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1654771"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2533488","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing: Expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"Muller","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: Fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/dmd.121.000503","article-title":"Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors","volume":"50","author":"Menezes","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"104979","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"Menzel","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Shi, R., Jia, L., Lv, Z., and Cui, J. (2025). Another power of antibody-drug conjugates: Immunomodulatory effect and clinical applications. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1632705"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies","volume":"77","author":"Harper","year":"2017","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e1433981","DOI":"10.1080\/2162402X.2018.1433981","article-title":"PD-1\/PD-L1 pathway: An adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer","volume":"7","author":"Dosset","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients with Urothelial Bladder Carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","article-title":"Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma","volume":"86","author":"Nordentoft","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","article-title":"Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma","volume":"126","author":"Shohdy","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MOU.0000000000001221","article-title":"Tumor-informed circulating tumor DNA in urothelial carcinoma: A promising novel biomarker","volume":"34","author":"Mehrazin","year":"2024","journal-title":"Curr. Opin. Urol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1093\/oncolo\/oyac037","article-title":"Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma","volume":"27","author":"Ravi","year":"2022","journal-title":"Oncologist"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3233\/BLC-201517","article-title":"Spectrum of FGFR2\/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma","volume":"7","author":"Grivas","year":"2021","journal-title":"Bladder Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2026.44.16_suppl.4569","article-title":"Longitudinal tumor-informed ctDNA monitoring and clinical outcomes in advanced urothelial carcinoma treated with enfortumab vedotin\u00b1pembrolizumab","volume":"44","author":"Ayanambakkam","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.6004\/jnccn.2026.0022","article-title":"Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines in Oncology","volume":"24","author":"Flaig","year":"2026","journal-title":"J. Nat. Compr. Cancer Netw."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s10147-024-02481-8","article-title":"Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: A prospective multicenter cohort study","volume":"29","author":"Taoka","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"17588359231192402","DOI":"10.1177\/17588359231192402","article-title":"Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer","volume":"15","author":"Parent","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative Biomarkers of Clinical Benefit with Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials","volume":"28","author":"Bellmunt","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated with Pembrolizumab Across 20 Cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lavallee, E., Sfakianos, J.P., and Mulholland, D.J. (2021). Tumor Heterogeneity and Consequences for Bladder Cancer Treatment. Cancers, 13.","DOI":"10.3390\/cancers13215297"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: Challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_121","unstructured":"ClinicalTrials.gov (2026, August 18). A Phase II, Open-Label, Single-Arm, Multi-Center. Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Upper Tract Urothelial Cancer (NEPTUNE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06356155."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1 + 1 > 2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_125","unstructured":"ClinicalTrials.gov (2026, August 18). A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06196736."},{"key":"ref_126","unstructured":"ClinicalTrials.gov (2026, August 18). A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination with Toripalimab Versus Standard Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06592326."},{"key":"ref_127","unstructured":"ClinicalTrials.gov (2026, August 18). IZABRIGHT-Bladder01: A Randomized, Open-Label, Phase 2\/3 Trial of Izalontamab Brengitecan Versus Platinum-Based Chemotherapy for Metastatic Urothelial Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07106762."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/14796694.2025.2535280","article-title":"SGNDV-001: Disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/JCO.2025.43.5_suppl.662","article-title":"A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1","volume":"43","author":"Iyer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"TPS895","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS895","article-title":"FORAGER-2: A randomized phase 3 study evaluating the efficacy and safety of vepugratinib combined with enfortumab vedotin and pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma with an FGFR3 genetic alteration","volume":"44","author":"Reimers","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/14796694.2026.2663956","article-title":"TROPION-Urothelial03: A phase II\/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma","volume":"22","author":"Galsky","year":"2026","journal-title":"Future Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e2400766","DOI":"10.1200\/PO-24-00766","article-title":"Assessing Nectin-4 as a predictive biomarker in urothelial carcinoma and other genitourinary malignancies","volume":"8","author":"Ozay","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Qin, S., Dai, Z., Hu, Z., Wang, X., Zhang, H., Yang, H., Liu, J., and Ma, L. (2026). The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: Clinicopathological correlations and implications for ADC-guided precision therapy. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1887794"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Reyes, K.R., Zhu, R., Herberts, C., Dutta, P., Wray, A., Mitchell, B., Balkhi, S.S., Zhu, X., Chu, C.E., and Porten, S.P. (Eur. Urol. Oncol., 2026). Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin \u00b1 Pembrolizumab, Eur. Urol. Oncol., in press.","DOI":"10.1016\/j.euo.2026.06.002"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.eururo.2024.11.012","article-title":"Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy","volume":"87","author":"Koshkin","year":"2025","journal-title":"Eur. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2743\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:59:08Z","timestamp":1787572748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":136,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172743"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172743","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}